56 results about "Tumour volume" patented technology

The invention discloses a hepatobiliary tumor follow-up visit data processing service system, and relates to the technical field of hepatobiliary tumor follow-up visit data processing. A data collection module is used for collecting hepatobiliary tumor growth and change conditions of a current patient in a current follow-up visit period; the tumor volume change rate OBL, the tumor growth speed OTS and the tumor growth predicted value OY are sequentially calculated and output, the change trend of the liver and gall tumors of the current patient is observed, basic data are provided for follow-up visit diagnosis and treatment, and the current patient is in the next follow-up visit period through a data prediction processing module. And taking the tumor growth predicted value OY of the last follow-up period as an input value of the tumor volume Ostart when follow-up of the next follow-up period starts to form continuous calculation of follow-up, so that efficient and accurate processing and analysis of tumor data are realized, the prediction accuracy is improved, and errors generated by prediction are corrected and adjusted in time; and more accurate treatment suggestions are provided for patients.

The application relates to the technical field of biological medicine, and discloses a micropeptide miPEP060 coded by a LINC00060 gene and application thereof; the application provides the following application of LINC00060 and the micropeptide miPEP060 coded thereby: preparing a product for predicting tumor chemotherapy efficacy, preparing a product for predicting tumor prognosis; preparing a tumor treatment product, preparing a product for enhancing tumor chemotherapy efficacy, preparing a product for overcoming tumor chemotherapy drug resistance, preparing a product for inhibiting PARP1 enzyme activity or PARylation modification, and preparing a product for inhibiting replication stress response and replication fork stability; the LINC00060 and the micropeptide miPEP060 coded thereby provided by the application can significantly enhance the chemotherapy killing effect of tumor cells or tumor tissues and reduce tumor volume.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The name of the invention is compositions and methods for enhancing cancer radiotherapy. A nutritional supplement comprising fish oil and selenium has been determined to enhance radiotherapy of tumors in a synergistic manner. The co-therapy of such supplements and radiotherapy results in a significantly improved reduction in tumor volume in animal models and reduces the common side effects, such as weight loss, inflammation and gastrointestinal tract damage, relative to radiotherapy alone. It has also been found that this co-therapy can reduce the incidence of metastasis from a primary implant site and modulate the expression of genes associated with apoptosis in tumor cells. Formulations of such supplements with good tolerance and palatability are also provided.

The present disclosure relates to representation learning for treatment response prediction of risk organs and total tumor volume. For predicting the response of radiation therapy, radiomics is used for unsupervised machine training of an encoder-decoder network to predict based on input of image data, such as computed tomography image data, and from segmentation. Then, the trained encoder is used to generate latent representations to be used as input to different classifiers or regressors for predicting the treatment response, such as one classifier for predicting the response for a risk organ and another classifier for predicting another type of response for a risk organ or predicting the response for a tumor.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

Potential prognostic biomarkers for CD26-targeted therapy were identified based on phase I study data of a humanized anti-CD26 monoclonal antibody YS110 against CD26-expressing tumors. Using boxplot analysis, scatter plot analysis, Pearson's product-moment correlation / Spearman's rank-difference correlation, bar graph analysis, and receiver operating characteristic (ROC), a correlation between soluble CD26 titer variation and tumor volume variation by YS110 administration, RECIST criteria evaluation, and progression-free survival (PFS) were examined. Further, mechanism of serum soluble CD26 titer variation was confirmed by in vitro experiments. As a result, serum soluble CD26 / DPP4 titer variation at an early stage of YS110 treatment was found for the first time as a predictive biomarker to evaluate a therapeutic effect.

The invention discloses a closed tumor-free drainage apparatus for abdominal tumors, which relates to the field of medical instruments, and comprises a protective sleeve, a sealing mechanism, a limiting mechanism and a sealing mechanism, the protective sleeve is used for protecting when drainage mass cyst fluid is used for reducing the volume of the tumors aiming at the huge tumors (cystic solid / cystic) of the pelvic and abdominal cavities, and the sealing mechanism is used for sealing and attaching the protective sleeve and the tumor cyst wall. The limiting device is arranged at the top of the protective sleeve and used for limiting and controlling the size of an opening in the top of the protective sleeve and sealing the whole protective sleeve after drainage operation is finished to prevent cystic fluid from flowing out to the pelvic cavity; by means of the protective sleeve, a drainage tube can penetrate through the interior of the protective sleeve to drain cyst fluid in the wrapping block in a clinical operation of excising a huge tumor of the pelvic cavity, the protective sleeve can protect drainage of the drainage tube and prevent the cyst fluid from flowing into the pelvic cavity and generating a spreading risk, and after the cyst fluid of the wrapping block is drained, the size of the wrapping block can be reduced, and the size of the wrapping block is reduced. In this way, excision operation can be conveniently conducted on the masses, and the length of an abdominal incision can be shortened during laparotomy.

The present application discloses an application of RAB32 in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer. In the present application, RAB32, a member of the small GTPase RAB family, is significantly more highly expressed in non-small cell lung cancer tissues and cell lines than in adjacent cancer tissues and normal cells, and is associated with a poor prognosis. In vitro experiments show that knocking down the highly expressed RAB32 gene in tumor cells can significantly inhibit the proliferation of lung adenocarcinoma cells. In an in vivo tumor-bearing mouse model, knocking down the RAB32 gene significantly reduced the tumor volume and inhibited its growth in the knockdown group, while also inhibiting the lymph node metastasis ability of lung adenocarcinoma cells. Therefore, the RAB32 gene can be used in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer.

The invention relates to the field of tumor volume detection, and discloses a TOF technology-based tumor volume detection device for a gastrointestinal endoscope, the TOF technology-based tumor volume detection device comprises a gastrointestinal endoscope body, a detection head is mounted on one side of the gastrointestinal endoscope body, and a CCD cable, a forceps tube, an air supply tube and a water supply tube are sequentially mounted in the detection head; illumination light sources are symmetrically mounted in the middle of the detection head, a mounting block is fixedly connected to one side of the detection head, an adjusting and limiting structure is fixedly mounted on one side of the mounting block, and a scraping plate is arranged on one side of the adjusting and limiting structure. The scraping plate can be driven by the adjusting limiting structure to clean one side of the detection head, the cleaning efficiency is enhanced through the water spraying structure when the scraping plate is cleaned, the position of the TOF sensor on the mounting block can be adjusted according to requirements by utilizing the adjusting limiting structure, the size of a tumor block is measured by utilizing the TOF sensor, and the detection efficiency is improved. And real volume data of the tumor in the body is obtained.

The invention discloses a personalized preoperative risk assessment method for a spinal tumor resection operation, and the method comprises the steps: carrying out the standardization processing of features extracted from the case data of a patient and the corresponding operation plan data, and obtaining the processed features; the method comprises the following steps: preprocessing medical image data to obtain preprocessed data, performing tumor segmentation on the data through a three-dimensional attention U-Net network to obtain a tumor voxel-level probability graph, and calculating a tumor volume; obtaining the type of the tumor through the preprocessed data, the double-flow deep network and the type discrimination network; respectively carrying out standardization processing on the type, the tumor volume, the extracted wettability score and the tumor position grade to form a third feature; obtaining basic weights of the processed features and the third features from a historical database, and then dynamically adjusting the basic weights to obtain a target weight; and performing weighted summation on the target weight, the processed feature and the third feature to obtain a risk score, and matching the risk score with a preset risk score to obtain a preoperative risk assessment level.

The present invention relates to the application of stiripentol in the preparation of anti-tumor drugs, and belongs to the field of biomedical technology. The present invention has found that stiripentol used for the treatment of epilepsy can reduce the activity of tumor cells such as non-small cell lung cancer, colorectal cancer, gastric cancer, etc., reduce tumor volume, prolong the survival time of tumor mice, and has a significant anti-tumor effect; stiripentol is used in combination with chemotherapy drugs, or in combination with radiotherapy, which can significantly enhance the anti-tumor effect, and stiripentol is used in combination with chemotherapy drugs or radiotherapy. There is a synergistic effect. The present invention has discovered a new use of stiripentol and expanded the application range of stiripentol. At the same time, stiripentol has good clinical safety and no toxic side effects, providing a new choice for clinical treatment drugs for tumors.

The invention discloses a high-throughput lung cancer gene screening system and method based on CRISPR (clustered regularly interspaced short palindromic repeats), and relates to the technical field of gene screening. According to the method, full-lung three-dimensional visualization and automatic classification and identification of the lung tissue tumor can be realized without tissue slicing, and the mass center of the tumor, the structural characteristics and the interaction relationship with the host tissue are extracted in combination with a space coordinate system. On the basis, the system constructs a multi-parameter risk evaluation index system, proposes a tumor comprehensive evaluation score S based on the shortest distance d between the tumor and the lung lobe surface in combination with the tumor volume V and the ratio R of tumor cells to host cells, and introduces a dual threshold judgment mechanism to perform risk grading on different tumor types. Compared with traditional two-dimensional slice morphology or sequencing enrichment scoring, the quantitative evaluation method can accurately identify structure invasion period and in-situ stable tumors.

This invention discloses a tumor volume detection device for gastrointestinal endoscopy based on Time-of-Flight (TOF) technology, specifically in the field of tumor volume detection technology. It includes a gastrointestinal endoscope body. The front end of the endoscope body includes a CCD cable, two illumination sources, an air supply pipe, a water supply pipe, and a forceps pipe. The air supply pipe and water supply pipe are located between the two illumination sources. The CCD cable is located at the top of the forceps pipe. A mounting plate is fitted onto the outer side of the front end of the endoscope body. This invention uses an electric telescopic rod to retract a toothed plate, which, through meshing with gears, drives a drive shaft and a support plate to rotate, rotating the TOF sensor between the two illumination sources. The tumor is then irradiated by the illumination sources. During irradiation, the TOF sensor measures the size of the tumor by calculating the time difference between the time of light emission and the time of light reflection. The overall structure facilitates the measurement of tumor size.

The present application provides a prognostic marker for neoadjuvant immunotherapy and chemotherapy of lung cancer, which is the change rate of tumor volume before and after early treatment of lung cancer. In the early treatment of lung cancer, by combining the method of artificial intelligence, the volume change of tumor lesion is used as the feature of treatment effect, and it is observed from the Kaplan-Meier curve that the change amount of tumor volume has a more obvious difference between the two groups of patients.

The present invention relates to a fusion protein comprising: an interleukin-21 (IL-21) polypeptide, and an antibody or antigen binding fragment that binds at least one of CD8a, CD8aa or CD8aß having

The invention relates to the technical field of tumor treatment, and discloses a CT-guided tumor ablation dose regulation and control method and system, and the method comprises the steps: obtaining the three-dimensional contour data and gray value distribution of a tumor through CT scanning, calculating the volume and average density of the tumor, and obtaining the initial ablation dose. Initial parameters of ablation equipment are set, an ablation program is started, data are updated at specific time intervals in the ablation process, and the real-time ablation dosage is calculated. And comparing the real-time ablation dose with the initial ablation dose, and adjusting the power of ablation equipment according to a specific formula and a comparison result. The system comprises an imaging and parameter acquisition module, an initial dose calculation module, an ablation equipment control module, a real-time monitoring module, a dose comparison and regulation module and the like. The ablation dosage can be accurately regulated and controlled according to the real-time condition of a tumor, the ablation treatment effect is improved, the damage risk to normal tissue is reduced, an alarm can be given to prompt an operator when the dosage is abnormal, and the high clinical application value is achieved.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

A composition of microparticles includes a non-radioactive and a radioactive isotope, and an injection vehicle, for use in the intratumoral treatment of cancer, by combined antitumoral effect of radioactivity and intratumoral microparticle deposition. The antitumoral effect provided by the cytotoxicity of radioactivity is enhanced by a modulation of the tumoral immune response induced by microparticle deposition inside the tumor, thereby decreasing the dose of radioactivity required to treat solid tumors. A method of treating solid tumors using a sub-optimal tumor-volume coverage dose of radioactivity combined with intratumoral microparticle deposition as a mean of tumor control is also disclosed.

Immunogenic compositions and systems, as well as methods for producing the immunogenic compositions, are disclosed. Also disclosed are compositions, systems, and methods of reducing cancer cell activity and treating cancer, as well as methods of reducing tumor volume and / or preventing an increase in tumor volume present in a living subject. The systems and methods involve applying an alternating electric field to cancer cells (before or after separation from a target portion of a subject), and irradiating the separated and treated cancer cells. The method may also include administering the irradiated and treated cancer cells back to the subject from which the cancer cells are separated, and / or applying an alternating electric field to the subject. The immunogenic composition includes a population of isolated and apoptotic cancer cells.

The invention provides a tumor magnetic sensitive signal extraction method and device based on an ESWAN sequence, equipment and a medium. The method comprises the following steps: acquiring a tumor phase diagram of a target part; inputting the tumor phase diagram into a preset medical image processing model, and sketching a suspected focus area in the tumor phase diagram to generate a focus sketching area; generating a three-dimensional region of interest according to the focus sketching region; based on the three-dimensional region of interest, the ratio of the magnetically sensitive signals within the volume of the tumor is obtained, and evaluation of the overall structure and heterogeneity of the tumor can be provided.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

The application discloses a non-small cell lung cancer fractionated radiotherapy progress prediction method based on a mathematical mechanism model, which is based on in-depth research on tumor proliferation mechanism and radiotherapy killing effect, and simultaneously carries out segmented integral analysis on the fractionated radiotherapy process, constructs a mathematical mechanism model considering dynamic growth change of tumor volume in the fractionated radiotherapy process, and realizes non-small cell lung cancer fractionated radiotherapy progress prediction by using the mathematical mechanism model. The application can use low-cost python software to realize one-key personalized simulation of NSCLC fractionated radiotherapy progress, provides a new visual angle of numerical simulation for doctors, accurately predicts the volume change of the tumor of a patient after fractionated radiotherapy, and provides a recommended scheme, potential opportunity, reference dose and interval frequency and the like for intervention and intervention of radiotherapy planning.

The invention discloses a GPC3 targeting chimeric antigen receptor gamma delta T cell and an application thereof in treatment of hepatocellular carcinoma. The CAR-gamma delta T cell has a third-generation CAR structure and has high targeting accuracy and killing efficiency, the in-vitro killing rate of GPC3 positive hepatoma carcinoma cells (HepG2 / Hep3B) is larger than 90% (the efficiency-target ratio is 10: 1) and is obviously improved compared with that of common gamma delta T cells, the tumor size is obviously reduced in a PDX mouse model, and the excellent treatment effect of the CAR-gamma delta T cell is proved.

The invention belongs to the field of medicines, and particularly relates to application of a BNLF2b gene in gastric cancer. Experiments show that BNLF2b overexpression can significantly inhibit the growth of EBV positive gastric cancer cells, and the tumor volume and weight of an AGS / EBV cell group of the overexpression BNLF2b are significantly smaller than those of a control group. Meanwhile, the BNLF2b enhances the antigen presentation capability by up-regulating the expression of HLA-I, activates the anti-tumor immune response of cytotoxic T cells, and blocks the immune escape mechanism of tumor cells by inhibiting the expression of JAK2 and PD-L1. Western blot analysis proves that the expression level of JAK2 and PD-L1 proteins of a BNLF2b overexpression group is remarkably reduced, and the expression level of HLA-I is remarkably improved. The discovery provides an important basis for developing a novel treatment strategy based on the BNLF2b gene, and has a wide clinical application prospect.

This disclosure relates to modulating IL-2 expression / activity to prevent or treat diseases (cancer, autoimmune diseases, inflammatory diseases, or infections). Compounds of formula (I), as well as compositions comprising their conjugates, complexes, and pharmaceutical compositions, as well as methods of using them to modulate (e.g., increase) IL-2 expression / activity to achieve desired results (e.g., reduction in cancer cell viability, growth, proliferation, or metastasis; reduction in tumor volume; increase in survival; increase or decrease in immune cell proliferation or activation; increase or decrease in cytokine production; decrease in autoimmunity; decrease in inflammation, etc.). Related pharmaceuticals, kits, and methods of delivering such compositions are described. Compounds of formula (I) and methods for developing or manufacturing their pharmaceutical compositions are provided. Diagnostic and test methods for detecting levels of IL-2 expression / activity, as well as compositions constituting diagnostic or test kits, are further described. JPEG2026513223000025.jpg3642

The utility model discloses a device suitable for measuring the volume of a tumor, and relates to the technical field of medical instruments, in particular to the device suitable for measuring the volume of the tumor, which comprises a measuring cylinder and a placing cylinder, and a communicating pipe is fixedly connected on the side wall of the middle part of the measuring cylinder; when the volume of an in-vitro tumor is measured, clear water is poured into a placing barrel, the water submerges a clamping part, the liquid level in the placing barrel is flush with an upper end opening of a communicating pipe, a circular plate is pushed by an air cylinder to ascend and move out of the liquid level, the tumor is placed on the circular plate, the air cylinder descends and drives all limiting assemblies to clamp the tumor, and the clamping part drives the tumor to be submerged in the water; the volume of the clamping part in the water is not changed, after the tumor is submerged in the water, the liquid level in the placing cylinder is raised, and discharged water caused by the fact that the tumor is submerged in the water flows into the measuring cylinder through the communicating pipe, so that the volume of the tumor is obtained by measuring the volume of the discharged water, and the volume of the tumor is accurately measured.

The application provides application of VPS53 in intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the technical field of biological medicine.The application takes VPS53 as the intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, finds that the copy number of VPS53 gene increases after long-term low-dose irradiation, and the expression level of VPS53 increases.In the thyroid cancer cell line with high expression of VPS53, the expression of VPS53 is knocked down, the proliferation, migration and invasion ability is weakened, the tumor volume is smaller, and the tumor grows more slowly;in the thyroid cancer cell line with low expression of VPS53, the expression of VPS53 is overexpressed, the proliferation, invasion and migration ability is enhanced, the tumor volume is larger, and the tumor grows faster.The application proves that knocking down VPS53 is a candidate intervention target of the occurrence and development of thyroid cancer caused by long-term low-dose ionizing radiation.